1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
3.8. Products in Pipeline
4. TECHNOLOGICAL OUTLOOK
5. TARGETED DRUG DELIVERY MARKET BY TYPE
5.1. Introduction
5.2. Active Targeting
5.3. Passive Targeting
6. TARGETED DRUG DELIVERY MARKET BY DELIVERY TYPE
6.1. Introduction
6.2. Liposomes
6.3. Nanoparticles
6.4. Monoclonal Antibody
6.5. Others
7. TARGETED DRUG DELIVERY MARKET BY APPLICATION
7.1. Introduction
7.2. Oncology
7.3. Cardiovascular Disease
7.4. Neurological Disease
7.5. Inflammatory Disease
7.6. Others
8. TARGETED DRUG DELIVERY MARKET BY END-USER
8.1. Introduction
8.2. Hospitals
8.3. Specialized Clinics & Centers
8.4. Others
9. TARGETED DRUG DELIVERY MARKET BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. By Type
9.2.2. By Delivery Type
9.2.3. By Application
9.2.4. By End-User
9.2.5. By Country
9.2.5.1. USA
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. South America
9.3.1. By Type
9.3.2. By Delivery Type
9.3.3. By Application
9.3.4. By End-User
9.3.5. By Country
9.3.5.1. Brazil
9.3.5.2. Argentina
9.3.5.3. Others
9.4. Europe
9.4.1. By Type
9.4.2. By Delivery Type
9.4.3. By Application
9.4.4. By End-User
9.4.5. By Country
9.4.5.1. Germany
9.4.5.2. France
9.4.5.3. United Kingdom
9.4.5.4. Spain
9.4.5.5. Italy
9.4.5.6. Others
9.5. Middle East and Africa
9.5.1. By Type
9.5.2. By Delivery Type
9.5.3. By Application
9.5.4. By End-User
9.5.5. By Country
9.5.5.1. Saudi Arabia
9.5.5.2. UAE
9.5.5.3. Others
9.6. Asia Pacific
9.6.1. By Type
9.6.2. By Delivery Type
9.6.3. By Application
9.6.4. By End-User
9.6.5. By Country
9.6.5.1. China
9.6.5.2. India
9.6.5.3. Japan
9.6.5.4. South Korea
9.6.5.5. Indonesia
9.6.5.6. Thailand
9.6.5.7. Taiwan
9.6.5.8. Others
10. COMPETITIVE ENVIRONMENT AND ANALYSIS
10.1. Major Players and Strategy Analysis
10.2. Market Share Analysis
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Competitive Dashboard
11. COMPANY PROFILES
11.1. Johnson & Johnson
11.2. F. Hoffmann-La Roche AG
11.3. Pfizer Inc.
11.4. Merck KgaA
11.5. Bristol Myers Squibb Company
11.6. Amgen Inc.
11.7. Eli Lilly And Company
11.8. Glaxosmithkline Plc
11.9. Astrazeneca Plc
11.10. AbbVie Inc.
12. APPENDIX
12.1. Currency
12.2. Assumptions
12.3. Base and Forecast Years Timeline
12.4. Key benefits for the stakeholders
12.5. Research Methodology
12.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES